This study successfully identified a subset of bladder cancer stem cells that respond to GALNT1 siRNA and SHH inhibitors, providing a potential strategy for prevention and targeted treatment for recurrent bladder cancer. Here, GALNT1 is linked to urinary bladder carcinoma.